Implementation of a molecular tumor board: The impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock medical center

Oncologist

Volumn 20, Issue 9, 2015, Pages 1011-1018

  Tafe, Laura J ^a   Gorlov, Ivan P ^a   De Abreu, Francine B ^a   Lefferts, Joel A ^a   Liu, Xiaoying ^a   Pettus, Jason R ^a   Marotti, Jonathan D ^a   Bloch, Kasia J ^a   Memoli, Vincent A ^a   Suriawinata, Arief A ^a   Dragnev, Konstantin H ^a   Fadul, Camilo E ^a   Schwartz, Gary N ^a   Morgan, Clinton R ^a   Holderness, Britt M ^a   Peterson, Jason D ^a   Tsongalis, Gregory J ^a   Miller, Todd W ^a   Chamberlin, Mary D ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Genetic profiling; Molecular tumor board; Next generation sequencing; Precision medicine; Targeted therapy

Indexed keywords

B RAF KINASE; BRIP1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SCATTER FACTOR RECEPTOR; TRAMETINIB; UNCLASSIFIED DRUG; DNA;

ADULT; ARTICLE; BIOPSY; BRAIN CANCER; BRAIN METASTASIS; BREAST CANCER; CANCER GENETICS; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; DECISION MAKING; DNA SEQUENCE; EPENDYMOMA; GENE MUTATION; GENETIC ASSOCIATION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SIGNAL TRANSDUCTION; SKIN CANCER; TREATMENT OUTCOME; CASE REPORT; DECISION SUPPORT SYSTEM; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR PATHOLOGY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

DECISION SUPPORT TECHNIQUES; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATHOLOGY, MOLECULAR; PRECISION MEDICINE;

EID: 84940654294     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0097     Document Type: Article

References (31)

1. Duffy MJ, O’Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011;37:151-159.
2. Tsimberidou AM, Iskander NG, Hong DS et al. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initia- tive. Clin Cancer Res 2012;18:6373-6383.
3. Tsimberidou AM, Wen S, Hong DS et al. Personalized medicine for patients with advanced cancer in the phase I program at M.D. Anderson: Validation and landmark analyses. Clin Cancer Res 2014;20:4827-4836.
4. Kim ES, Herbst RS, Wistuba II et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
5. Tsongalis GJ, Peterson JD, de Abreu FB et al. Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 2014; 52:707-714.
6. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
7. Forbes SA, Tang G, Bindal N et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010;38: D652-D657
8. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res 2011;39: e118
9. UniProt Consortium. Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 2013;41:D43-D47
10. Landrum MJ, Lee JM, Riley GR et al. ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42:D980-D985.
11. Sherry ST, Ward MH, Kholodov M et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-311.
12. Balko JM, Giltnane JM, Wang K et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014;4:232-245.
13. Schmid S, Siano M, Joerger M et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2015;87:85-87.
14. Robinson SD, O’Shaughnessy JA, Cowey CL et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014; 85:326-330.
15. Planchard D, Mazieres J, Riely GJ et al. Interim results of phase ii study brf 113928 of dabrafenib in braf v600e mutation-positive non-small cell lung cancer (nsclc) patients. J Clin Oncol 2013;31:8009a
16. South CD, Hampel H, Comeras I et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008;100: 277-281.
17. Martin SA, McCarthy A, Barber LJ et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009;1:323-337.
18. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014;124:3420-3430
19. Banerjee S, Crouse NR, Emnett RJ et al. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rhebindependent manner. Proc Natl Acad Sci USA 2011; 108:15996-16001.
20. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl JMed 2011;364:514-523.
21. Cheung LW, Yu S, Zhang D et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 2014;26: 479-494.
22. Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006; 78:255-260.
23. Tetef ML, Margolin KA, Doroshow JH et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000;46:19-26.
24. Schwaederle M, Parker BA, Schwab RB et al. Molecular tumorboard:TheUniversity of California-San Diego Moores Cancer Center experience. The Oncologist 2014;19:631-636
25. Johnson DB, Dahlman KH, Knol J et al. Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The Oncologist 2014;19:616-622.
26. Johnson BE, Mazor T, Hong C et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343: 189-193.
27. Ouyang L, Lee J, Park CK et al. Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas. BMC Med Genomics 2014;7:2
28. Vakiani E, Janakiraman M, Shen R et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30:2956-2962.
29. Wagle N, Grabiner BC, Van Allen EM et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014;371: 1426-1433.
30. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-3096.
31. Maria Schwaederle, Barbara A. Parker, Richard B. Schwab et al. Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. The Oncologist 2014;19:631-636